Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Non-Current Deffered Revenue (2020 - 2025)

IDEAYA Biosciences' Non-Current Deffered Revenue history spans 4 years, with the latest figure at $1.7 million for Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue changed N/A year-over-year to $1.7 million; the TTM value through Sep 2025 reached $1.7 million, changed N/A, while the annual FY2022 figure was $5.2 million, 83.38% down from the prior year.
  • Non-Current Deffered Revenue for Q3 2025 was $1.7 million at IDEAYA Biosciences, down from $5.2 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $52.1 million in Q1 2021 and bottomed at $1.7 million in Q3 2025.
  • The 3-year median for Non-Current Deffered Revenue is $10.2 million (2022), against an average of $22.5 million.
  • The largest annual shift saw Non-Current Deffered Revenue fell 15.02% in 2021 before it tumbled 83.38% in 2022.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $31.2 million in 2021, then crashed by 83.38% to $5.2 million in 2022, then plummeted by 67.68% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for IDYA's Non-Current Deffered Revenue are $1.7 million (Q3 2025), $5.2 million (Q4 2022), and $7.3 million (Q3 2022).